Stem cell therapy in Mexico: why here, and not Panama or Cayman?

Stem cell therapy in Mexico is regulated by COFEPRIS, Mexico's federal health regulator. We built Celva in Tijuana because Hospital Angeles, Tijuana is about 20 miles and 25 to 30 minutes by car from San Diego.

Take any one variable alone and the winner isn't Mexico. Germany edges it on records. Japan edges it on basic science.

Start with Why Mexico, for Americans See every comparison
  1. San Diego
  2. San Ysidro
  3. Tijuana
About 20 miles, and 25 to 30 minutes from San Diego.

Is Mexico the best country for stem cell therapy?

The case isn't that Mexico is the best. It's that geography compounds.

  • If the question were only regulation,

    Germany or Japan would win: older industries and a deeper paper trail.

  • If the question were only cost,

    Thailand or India would win.

  • If it were only privacy,

    Cayman would win.

  • The reason Mexico keeps coming out on top in our internal comparisons, and the reason we built Celva there, is that none of those questions exists in isolation for an American patient.

Treatment at Celva is one day, and most patients are home the same day. The care around it runs longer: follow-up calls at 1 week, then at 1, 3 and 6 months, then once a year, and physical therapy for joint and spine patients. If a follow-up review ever calls for a return visit, it's a day trip by car, not an international flight. Distance matters because follow-through matters.

This section isn't arguing that Mexico is the unique answer. The comparisons say where Mexico is behind: Germany has deeper records, Japan has deeper science. The argument is narrower: when you compound geography, regulation and hospital infrastructure, Mexico is the one where all three meet for an American patient.

Distance, regulation and hospitals, in one city

How far is Tijuana from San Diego?

  • Tijuana about 25 to 30 minutes from San Diego
  • Panama a flight of about 6.5 hours from Los Angeles, and a customs declaration
  • Cayman connecting flights from most U.S. cities

From San Diego, a Celva driver reaches Hospital Angeles, Tijuana in about 25 to 30 minutes. Pickup is anywhere in Southern California: your home, a hotel, the SAN curb, even LAX. (Yes, we'll come that far.) A patient can land at SAN in the morning, be at the hospital by mid-morning, and be home the same day.

There is one treatment day and no observation stay. Follow-up is by phone or video. The drive back crosses through the medical lane, and a return visit, if a follow-up review ever calls for one, is a day trip, not an international one.

Is stem cell therapy legal in Mexico?

Yes. Cell therapy in Mexico is regulated by COFEPRIS, the federal health regulator. That includes the allogeneic (donor) umbilical-cord MSC preparations Celva uses, given by licensed physicians inside Hospital Angeles, Tijuana.

Germany, Japan, Panama and Cayman each regulate cell therapy in their own way. The global regulatory map sets the frameworks side by side.

Mexico Regulated by COFEPRIS United States FDA, 21 CFR 1271

What if you need a hospital?

Celva treats inside Hospital Angeles, Tijuana, a 116-bed private hospital. ICU, emergency and imaging are in the same building. Cell therapy is a procedure, but it sometimes becomes a hospital. Being inside one matters.

When you stack the three variables that actually predict outcomes for an American patient (distance, framework, hospital backstop), they compound at the intersection, and the intersection happens to be in Tijuana.

How many Americans go to Mexico for medical care?

1.2 million

U.S. residents per year who go to Mexico for medical or dental care, by one widely quoted estimate.
Patients Beyond Borders estimate

Which comparison should you read first?

Each one stands on its own. Read in order, they build one comparison; read singly, each answers one question. Nobody's checking which order you pick.

  1. Why Mexico, for Americans

    The case for Mexico from an American patient's vantage. Proximity, regulator alignment, continuity of care, and the practical realities of cross-border treatment.

    If you read one, read this one

  2. Mexico vs. Panama and Cayman

    A side-by-side on the three Latin-American destinations Americans most often consider. Regulatory framework, hospital infrastructure, distance.

  3. Mexico vs. Germany and Japan

    The other two regulated destinations Americans actually fly to. Germany's hospital-exemption pathway and Japan's tiered regenerative-medicine law, side by side with Mexico.

  4. Tijuana, not Cancún

    Why Mexican medical tourism happens at the border, not at the beach. Hospital density, U.S. proximity, ground transit.

  5. The global regulatory map

    Six distinct frameworks, on one page: COFEPRIS (Mexico), MINSA (Panama), Health Practice Commission (Cayman), PEI (Germany), PMDA (Japan), INVIMA (Colombia).

What this section will not tell you

An editorial discipline, not a marketing one. Read it once before you start.

  1. A claim that Mexico is safer than the U.S.

    It isn't. It's comparably safe inside internationally accredited facilities for the procedures we run. The article on safety is the one that spells out the actual numbers.

  2. An argument that Panama and Cayman are scams.

    They aren't. There are good clinics in both. They sit under different rules and a longer trip, which we judged, on balance, a worse fit for an American patient. Reasonable people disagree.

  3. A reason to skip Germany or Japan.

    For some indications and some patients, they are the right answer and we will say so. The comparison article spells out which indications and which patients.

  4. A travelogue. "You'll love Tijuana."

    Maybe you will. That's not the relevant question. The relevant question is whether Tijuana solves a logistical problem that other destinations do not. The article on the city, not the country, walks through that.

  5. A claim that our practice is the only good one.

    It isn't. We can name three Tijuana clinics we'd send a family member to, and one we'd send to over us for a specific indication. That conversation belongs on a consult call, not a section landing page.

Start with the American vantage. It frames the rest.

If you're going to read one article in this section, make it this one. Most of the questions we get on consult calls trace back to the proximity-plus-regulation argument it makes.

Read Why Mexico, for Americans Back to the Learn library